


## VU0405601

Cat. No.:	HY-116759
CAS No.:	712325-30-9
Molecular Formula:	C <sub>17</sub> H <sub>13</sub> BrN <sub>2</sub> O <sub>2</sub>
Molecular Weight:	357.2
Target:	Potassium Channel
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	VU0405601 is a potent KV11.1 channel activator. VU0405601 protects cardiac tissue from dofetilide (HY-B0232)-induced ventricular tachycardia <sup>[1][2]</sup> .
IC <sub>50</sub> & Target	KV11.1 <sup>[1]</sup>
In Vitro	VU0405601 (5 μM; pretreated for 30 min before 100 nm dofetilide) protects cardiac tissue from dofetilide (HY-B0232)-induced ventricular tachycardia <sup>[2]</sup> . VU0405601 (50 μM) can be used as a hERG agonist and increases test pulse and tail currents, increases the IC <sub>50</sub> of dofetilide from 38.7 to 76.3 nm <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Egly CL, et al. A High-Throughput Screening Assay to Identify Drugs that Can Treat Long QT Syndrome Caused by Trafficking-Deficient KV11.1 (hERG) Variants. *Mol Pharmacol.* 2022 Apr;101(4):236-245.

[2]. Potet F, et al. Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias. *J Biol Chem.* 2012 Nov 16;287(47):39613-25.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA